Neovacs signs €65M China deal; Another biotech CEO chatters on about a possible buyout
• Paris-based Neovacs says it signed up BioSense Global for a €65 million deal covering the development of its IFNα Kinoid vaccine to treat lupus and dermatomyositis in the Chinese market. BioSense CEO Andy Li says he will launch a Phase III in China for the drug, provided it clears an ongoing Phase IIb trial conducted by Neovacs. The cash covers an upfront and milestones, though the announcement didn’t break out the prices.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.